Edition:
United States

Spectrum Pharmaceuticals Inc (SPPI.O)

SPPI.O on Nasdaq

6.87USD
29 Jul 2016
Change (% chg)

$0.05 (+0.73%)
Prev Close
$6.82
Open
$6.82
Day's High
$6.89
Day's Low
$6.77
Volume
412,645
Avg. Vol
747,216
52-wk High
$7.74
52-wk Low
$4.14

Select another date:

Wed, Jul 13 2016

BRIEF-Spectrum says unit Allos Therapeutics and Fresenius Kabi USA reach settlement to resolve patent litigation

* Spectrum says unit Allos Therapeutics and Fresenius Kabi USA entered into settlement agreement to resolve patent litigation relating to Folotyn

BRIEF-Spectrum Pharmaceuticals' unit, Allos Therapeutics and Sandoz enter settlement agreement

* On June 8, 2016, co's unit , Allos Therapeutics and Sandoz Inc entered into a settlement agreement

D.C. Circuit will not to block generic version of Spectrum's Fusilev

By Brendan Pierson A federal appeals court has refused to block Novartis AG unit Sandoz Inc from making a generic version of Spectrum Pharmaceuticals Inc's drug Fusilev, which is used to counteract the toxic effects of a widely used chemotherapy drug.

BRIEF-Spectrum Pharma says Dr Reddy's will be permitted to market generic version of Folotyn in US on Dec 1, 2022 or earlier

* Co's unit, dr. Reddy's labs, ltd entered into settlement agreement to resolve their patent litigation relating to folotyn

BRIEF-Spectrum Pharma says unit, Teva enter settlement agreement

* Unit, teva pharmaceuticals usa, inc. Entered into settlement agreement to resolve patent litigation relating to Folotyn

BRIEF-Spectrum Pharmaceuticals Q1 loss per share $0.14

* Spectrum Pharmaceuticals reports first quarter 2016 financial results and pipeline update

BRIEF-FDA grants orphan drug exclusivity to Spectrum Pharmaceutical's Evomela(tm)

* FDA grants orphan drug exclusivity to Evomela(tm) (melphalan) for injection, indicated for multiple myeloma

BRIEF-Spectrum Pharmaceuticals says FDA grants approval of Evomela for injection

* FDA grants spectrum pharmaceuticals approval of Evomela(tm) (melphalan) for injection Source text for Eikon: Further company coverage: (Bengaluru Newsroom +91 80 6749-1130; within U.S. +1 646 223 8780)

Select another date: